EARLY BACTERICIDAL ACTION OF PULSED EXPOSURE TO RIFAMPICIN, ETHAMBUTOL, ISONIAZID AND PYRAZINAMIDE IN PULMONARY TUBERCULOSIS PATIENTS

被引:0
|
作者
PARAMASIVAN, CN [1 ]
HERBERT, D [1 ]
UMAPATHY, KC [1 ]
RAHMAN, F [1 ]
KRISHNAMURTHY, PV [1 ]
PRABHAKAR, R [1 ]
机构
[1] TB RES CTR,SPURTANK RD,MADRAS 600031,INDIA
关键词
EARLY BACTERICIDAL ACTIVITY; PULSED EXPOSURE; SHORT COURSE CHEMOTHERAPY;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The bactericidal action of two therapeutic regimens on Mycobacterium tuberculosis was assessed by viable counts in serial sputum samples in 49 pulmonary tuberculosis patients being treated with rifampicin (R), ethambutol (Emb), isoniazid (I) and pyrazinamide (Z) together in a single dose thrice weekly (REmbIZ3) or with REmb and IZ on alternate days (REmb3IZ3alt). In both groups of patients, there was a significant reduction (P less-than-or-equal-to 0.02) in the colony forming units (cfu) of M. tuberculosis per ml of sputum during the first two days of treatment itself. This early bactericidal action (EBA) as well as the reduction in counts during the subsequent days of treatment were similar (P >0.2) for both REmbIZ3 and REmbIZ3alt regimens indicating that splitting up REmbIZ into REmb on one day and IZ on the next day in short course chemotherapy (SCC) regimens may not affect the bactericidal action of the regimens.
引用
收藏
页码:1 / 4
页数:4
相关论文
共 50 条
  • [1] BACTERICIDAL ACTION OF PULSED EXPOSURE TO RIFAMPICIN, ETHAMBUTOL, ISONIAZID AND PYRAZINAMIDE ON MYCOBACTERIUM-TUBERCULOSIS IN-VITRO
    PARAMASIVAN, CN
    HERBERT, D
    PRABHAKAR, R
    INDIAN JOURNAL OF MEDICAL RESEARCH SECTION A-INFECTIOUS DISEASES, 1993, 97 : 145 - 150
  • [2] Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis
    Botha, FJH
    Sirgel, FA
    Parkin, DP
    vandeWal, BW
    Donald, PR
    Mitchison, DA
    SOUTH AFRICAN MEDICAL JOURNAL, 1996, 86 (02): : 155 - 158
  • [4] Effect of Metformin on Plasma Exposure of Rifampicin, Isoniazid, and Pyrazinamide in Patients on Treatment for Pulmonary Tuberculosis
    Kumar, Agibothu Kupparam Hemanth
    Kadam, Abhijit
    Karunaianantham, Ramesh
    Tamizhselvan, Manoharan
    Padmapriyadarsini, Chandrasekaran
    Mohan, Anant
    Jeyadeepa, B.
    Radhakrishnan, Ammayappan
    Singh, Urvashi B.
    Bapat, Shraddha
    Mane, Aarti
    Kumar, Pradeep
    Mamulwar, Megha
    Bhavani, Perumal Kannabiran
    Haribabu, Hemalatha
    Rath, Nibedita
    Guleria, Randeep
    Khan, Abdul Mabood
    Menon, Jaykumar
    THERAPEUTIC DRUG MONITORING, 2024, 46 (03) : 370 - 375
  • [5] No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients
    Nardotto, Glauco Henrique Balthazar
    Bollela, Valdes Roberto
    Rocha, Adriana
    Della Pasqua, Oscar
    Lanchote, Vera Lucia
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (02): : 514 - 523
  • [7] Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children
    Aparna Mukherjee
    Thirumurthy Velpandian
    Mohit Singla
    Kunwar Kanhiya
    Sushil K Kabra
    Rakesh Lodha
    BMC Infectious Diseases, 15
  • [8] Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children
    Mukherjee, Aparna
    Velpandian, Thirumurthy
    Singla, Mohit
    Kanhiya, Kunwar
    Kabra, Sushil K.
    Lodha, Rakesh
    BMC INFECTIOUS DISEASES, 2015, 15
  • [9] PK/PD OF RIFAMPICIN, ISONIAZID, PYRAZINAMIDE, AND ETHAMBUTOL IN MACROPHAGES INFECTED WITH M. TUBERCULOSIS
    Ximenez, J. B.
    Nardotto, G. Balthazar
    Masson, A.
    Riul, T. Bachelli
    Rocha, A.
    Svensson, E. M.
    Lanchote, V.
    Baruffi, M. D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S59 - S60
  • [10] Therapeutic monitoring of isoniazid, rifampicin, ethambutol and pyrazinamide serum levels in the treatment of active pulmonary tuberculosis and determinants of their serum concentrations
    Kayhan, Servet
    Akgunes, Alper
    AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY, 2011, 5 (17): : 2035 - 2041